Evidence map›Paper›PMID 28820644›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2017

National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer.

Christopher P Childers, Kimberly K Childers, Melinda Maggard-Gibbons, James Macinko

Erratum issued 2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 177 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
177citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04533555 nacompletednot on this mapstarted 2020, after this paper: background citation

Randomized Trial of Universal vs. Guideline-directed Germline Testing Among Young Adults With Cancer

TypeinterventionalSponsorUniversity of PennsylvaniaRan2020 to 2025Enrolled749ConditionsCancerArmsBroad gene panel for young adult cancers, Standard
NCT07052266 narecruitingnot on this mapstarted 2025, after this paper: background citation

Feasibility of Obstetric and Cancer Universal Screening

TypeinterventionalSponsorWeill Medical College of Cornell UniversityRan2025 to 2028Enrolled550ConditionsHereditary Cancer SyndromesArmsMyRisk Hereditary Cancer Test
3 · Its place in the literature

Who cites it

177 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. The Genetic Education for Men (GEM) Trial: Development of Web-Based Education for Untested Men in BRCA1/2-Positive Families.Journal of cancer education : the official journal of the American Association for Cancer Education · 2021
    Trial
  12. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019
    Trial
  13. Trial
  14. Trial
  15. Article
  16. Article
  17. Article
  18. Measuring disease likelihood in genomic ascertainment.American journal of human genetics · 2026
    Article
  19. Article
  20. Article

117 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Christopher P ChildersChristopher P. Childers and Melinda Maggard-Gibbons, David Geffen School of Medicine at University of California-Los Angeles; Christopher P. Childers and James Macinko, Fielding School of Public Health at University of California-Los Angeles; and Kimberly K. Childers, Providence Health & Services Southern California, Los Angeles, California.
Kimberly K ChildersChristopher P. Childers and Melinda Maggard-Gibbons, David Geffen School of Medicine at University of California-Los Angeles; Christopher P. Childers and James Macinko, Fielding School of Public Health at University of California-Los Angeles; and Kimberly K. Childers, Providence Health & Services Southern California, Los Angeles, California.
Melinda Maggard-GibbonsChristopher P. Childers and Melinda Maggard-Gibbons, David Geffen School of Medicine at University of California-Los Angeles; Christopher P. Childers and James Macinko, Fielding School of Public Health at University of California-Los Angeles; and Kimberly K. Childers, Providence Health & Services Southern California, Los Angeles, California.
James MacinkoChristopher P. Childers and Melinda Maggard-Gibbons, David Geffen School of Medicine at University of California-Los Angeles; Christopher P. Childers and James Macinko, Fielding School of Public Health at University of California-Los Angeles; and Kimberly K. Childers, Providence Health & Services Southern California, Los Angeles, California.

Funding

Variation in Surgeon-Level Intraoperative Costs: An Intervention StudyF32HS025079 · AHRQ · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHILDERS, CHRISTOPHER · 2016 to 2018
$203k
AHRQ HHS F32 HS025079
6 · The paper itself

Abstract

Purpose In the United States, 3.8 million women have a history of breast (BC) or ovarian cancer (OC). Up to 15% of cases are attributable to heritable mutations, which, if identified, provide critical knowledge for treatment and preventive care. It is unknown how many patients who are at high risk for these mutations have not been tested and how rates vary by risk criteria. Methods We used pooled cross-sectional data from three Cancer Control Modules (2005, 2010, 2015) of the National Health Interview Survey, a national in-person household interview survey. Eligible patients were adult females with a history of BC and/or OC meeting select 2017 National Comprehensive Cancer Network eligibility criteria on the basis of age of diagnosis and family history. Outcomes included the proportion of individuals reporting a history of discussing genetic testing with a health professional, being advised to undergo genetic testing, or undergoing genetic testing for BC or OC. Results Of 47,218 women, 2.7% had a BC history and 0.4% had an OC history. For BC, 35.6% met one or more select eligibility criteria; of those, 29.0% discussed, 20.2% were advised to undergo, and 15.3% underwent genetic testing. Testing rates for individual eligibility criteria ranged from 6.2% (relative with OC) to 18.2% (diagnosis ≤ 45 years of age). For OC, 15.1% discussed, 13.1% were advised to undergo, and 10.5% underwent testing. Using only four BC eligibility criteria and all patients with OC, an estimated 1.2 to 1.3 million individuals failed to receive testing. Conclusion Fewer than one in five individuals with a history of BC or OC meeting select National Cancer Comprehensive Network criteria have undergone genetic testing. Most have never discussed testing with a health care provider. Large national efforts are warranted to address this unmet need.

Indexed as

Quality of Health CareAdultAgedBreast NeoplasmsCross-Sectional StudiesDatabases, FactualFemaleGenetic Predisposition to DiseaseGenetic TestingHumansMiddle AgedNeeds AssessmentOvarian NeoplasmsPredictive Value of TestsPrevalenceRetrospective Studies

Identifiers

PMID28820644
PMCPMC5707208

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.